Last updated: February 20, 2026
What is the drug associated with NDC 00781-6185?
NDC 00781-6185 corresponds to Ilumya (tildrakizumab-asmn), a monoclonal antibody used to treat moderate-to-severe plaque psoriasis. It is marketed by Sun Pharmaceutical Industries.
How does the market landscape look?
Market Size and Growth
- The global psoriasis treatment market was valued at $5.4 billion in 2022.
- Expected compound annual growth rate (CAGR): 8% (2023-2028).
- Major players include AbbVie, Johnson & Johnson, Amgen, Sun Pharma.
Key Competitors
| Product |
Indication |
Price per dose |
Administration schedule |
Market share (2022) |
| Humira (adalimumab) |
Psoriasis, other inflammatory diseases |
~$2,600 |
Every 2 weeks (initial), then every 4 weeks |
35% |
| Cosentyx (secukinumab) |
Psoriasis, ankylosing spondylitis |
~$4,900 |
Monthly after initial doses |
22% |
| Skyrizi (risankizumab) |
Psoriasis |
~$5,500 |
Every 12 weeks |
15% |
| Ilumya (tildrakizumab) |
Psoriasis |
~$4,300 |
Every 12 weeks |
4% (marketed niche) |
Regulatory and Market Access
- Approved by the FDA in 2018.
- Available via specialty pharmacies and injectables in office settings.
- Reimbursement largely depends on formulary inclusion and patient assistance programs.
Price Trends and Projections
Historical Pricing Data
- Launch price (2018): approximately $4,500 per dose.
- Adjusted for inflation, current price: ~$4,300–$4,500 per dose.
- Price stabilization observed over past 2 years, with minimal fluctuations.
Price Drivers
- Competition from biosimilars and newer agents.
- Patent exclusivity until at least 2030.
- Reimbursement negotiations, payer restrictions.
- Manufacturing costs remain stable.
Future Price Outlook (2023-2028)
| Year |
Estimated Price per Dose |
Rationale |
| 2023 |
~$4,300–$4,500 |
Stable due to limited biosimilar competition |
| 2024 |
~$4,200–$4,400 |
Potential pressure from biosimilar entries |
| 2025 |
~$4,000–$4,200 |
Biosimilar approvals in key markets begin |
| 2026 |
~$3,800–$4,000 |
Increased biosimilar availability, market share shifts |
| 2027 |
~$3,600–$3,800 |
Market stabilizes; biosimilars gain prevalence |
| 2028 |
~$3,500–$3,700 |
Continued price erosion as biosimilar market matures |
Note: The projections assume no major regulatory or market disruptions. Price reductions may be accelerated if biosimilar competition intensifies earlier than anticipated.
Implications for Stakeholders
- Manufacturers: Maintain differentiated positioning through patient access programs.
- Payers: Seek formulary negotiations to contain costs.
- Investors: Watch biosimilar market entries; biosimilars for tildrakizumab are unlikely before 2025.
Key Takeaways
- NDC 00781-6185 (Ilumya) operates in a competitive, mature psoriasis biologic segment.
- Current pricing remains stable around $4,300 per dose, with modest declines expected owing to biosimilar proliferation.
- Price erosion projected to accelerate post-2024, influenced by biosimilar market entry and generics.
- The market is expected to consolidate around $3,500–$4,000 per dose by 2028, with continued patent protection delaying more significant price reductions.
FAQs
1. Will Ilumya experience biosimilar competition before 2025?
Unlikely. Biosimilars for tildrakizumab are not FDA-approved yet, and regulatory pathways typically require several years.
2. How does Ilumya’s price compare to competitors?
Ilumya's approximate $4,300-dose is lower than newer agents like Skyrizi and Cosentyx, which range above $4,900 per dose. It is comparable or slightly lower than Humira, which has widespread biosimilar competition.
3. What factors could influence pricing outside of biosimilar competition?
Patent extensions, formulary negotiations, payer restrictions, and new indications could affect future price points.
4. Are there significant off-label uses impacting market share?
No. Ilumya's approved indication is limited to plaque psoriasis, with off-label uses minimal and not significantly impacting market dynamics.
5. How does reimbursement policy affect Ilumya’s market access?
Coverage depends on payer formulary inclusion; patient assistance programs mitigate access barriers but do not influence list prices directly.
Sources
- Grand View Research. (2023). Psoriasis Treatment Market Size & Trends.
- U.S. Food and Drug Administration. (2018). FDA Approval for Ilumya.
- IQVIA. (2022). Biologic and biosimilar market reports.
- Sun Pharmaceutical Industries. (2023). Product information for Ilumya.
- Drug Channels Institute. (2023). Biologic pricing and market access insights.
